Semaglutide (Ozempic®) 0.25mg and 1mg solution for injection in a pre-filled pen are available but will have intermittent supply throughout 2024. New patient initiations cannot be supported. 

Semaglutide (Ozempic®) 0.5mg solution for injection in a pre-filled pen is out of stock until early June 2024. This product will then have intermittent supply until the end of 2024. New patient initiations cannot be supported. 

Semaglutide (Rybelsus®) 3mg, 7mg and 14mg tablets are available and can support increased demand for both new patient initiations and any patients unable to obtain their existing GLP-1 RA therapy. 

Dulaglutide (Trulicity®) 0.75mg, 1.5mg, 3mg and 4.5mg solution for injection in a pre-filled pen are available but will have intermittent supply throughout 2024. New patient initiations cannot be supported. 

Liraglutide (Victoza®) 6mg/ml solution for injection in a pre-filled pen is out of stock until end of 2024. 

Exenatide (Bydureon BCise®) 2mg/0.85ml prolonged-release pre-filled pens remain available for patients stabilised on therapy but are not able to support new patient initiations. 

Exenatide (Byetta®) 5micrograms/0.02ml and 10micrograms/0.04ml pre-filled pens will be discontinued at the end of March 2024. 

Tirzepatide (Mounjaro® Kwikpens®) pre-filled pens are currently waiting to be assessed by the Scottish Medicines Consortium (SMC) and therefore their use is not recommended for the NHS in Scotland at this stage. Further advice will follow pending the SMC decision.